TITLE:
Study Evaluating ReFacto AF in Severe Hemophilia A

CONDITION:
Hemophilia A

INTERVENTION:
ReFacto AF

SUMMARY:

      To characterize the safety and efficacy of ReFacto AF in treating acute bleeding episodes
      during prophylaxis treatment, including neoantigenicity.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 12 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Severe hemophilia A (FVIII:C less than or equal to 2% at local laboratory)

          -  Previously treated patients with greater than or equal to 250 exposure days to any
             Factor VIII product

          -  Age greater than or equal to 12 years

          -  History of prophylaxis dosing at least twice per week on any Factor VIII product for
             at least 3 consecutive months within the 2 years prior to study enrollment unless the
             patient completed the previous pharmacokinetic study

          -  Adequate laboratory results

        Exclusion Criteria:

          -  Presence of any bleeding disorder in addition to hemophilia A

          -  Concomitant therapy with immunosuppressive drugs

          -  Current or historical Factor VIII inhibitor

          -  Treatment with any investigational drug or device within the past 30 days
      
